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Background. Protein encoding genes have long been the major targets for research in schizophrenia genetics. However, with
the identification of regulatory microRNAs (miRNAs) as important in brain development and function, miRNAs genes have
emerged as candidates for schizophrenia-associated genetic factors. Indeed, the growing understanding of the regulatory
properties and pleiotropic effects that miRNA have on molecular and cellular mechanisms, suggests that alterations in the
interactions between miRNAs and their mRNA targets may contribute to phenotypic variation. Methodology/Principal
Findings. We have studied the association between schizophrenia and genetic variants of miRNA genes associated with brain-
expression using a case-control study design on three Scandinavian samples. Eighteen known SNPs within or near brain-
expressed miRNAs in three samples (Danish, Swedish and Norwegian: 420/163/257 schizophrenia patients and 1006/177/293
control subjects), were analyzed. Subsequently, joint analysis of the three samples was performed on SNPs showing marginal
association. Two SNPs rs17578796 and rs1700 in hsa-mir-206 (mir-206) and hsa-mit-198 (mir-198) showed nominal significant
allelic association to schizophrenia in the Danish and Norwegian sample respectively (P=0.0021 & p=0.038), of which only
rs17578796 was significant in the joint sample. In-silico analysis revealed that 8 of the 15 genes predicted to be regulated by
both mir-206 and mir-198, are transcriptional targets or interaction partners of the JUN, ATF2 and TAF1 connected in a tight
network. JUN and two of the miRNA targets (CCND2 and PTPN1) in the network have previously been associated with
schizophrenia. Conclusions/Significance. We found nominal association between brain-expressed miRNAs and schizophre-
nia for rs17578796 and rs1700 located in mir-206 and mir-198 respectively. These two miRNAs have a surprising large number
(15) of targets in common, eight of which are also connected by the same transcription factors.
Citation: Hansen T, Olsen L, Lindow M, Jakobsen KD, Ullum H, et al (2007) Brain Expressed microRNAs Implicated in Schizophrenia Etiology. PLoS
ONE 2(9): e873. doi:10.1371/journal.pone.0000873
INTRODUCTION
Schizophrenia is a severe psychiatric disorder with a strong and
complex genetic disposition [1], but still with a largely unknown
etiology. Most research in schizophrenia genetics has been focused
on protein encoding genes. However, the advent of tiling arrays
has shown that a much larger fraction of the human genome is
actively transcribed [2–4]. Among the transcripts a growing
number of genes that encode active RNA species have been
identified, suggesting that regulatory RNAs also need to be
considered when trying to elucidate the etiology of diseases[5].
microRNAs (miRNA) constitute one class of the newly
discovered non-coding RNAs. The primary miRNA transcripts
are characterized by a hairpin structure, which guides the
subsequent processing of the miRNA into the mature form of
a short (19–24 nt) single stranded molecule. miRNAs have been
shown to control mRNA stability and translation by binding to
complementary sequence motives in the target mRNAs[6].
Individual miRNAs have been shown experimentally to affect
the mRNA levels of dozens of genes [7], thus supporting in silico
analyses [7,8] and suggesting that individual miRNA have
pleiotrophic effects on cellular processes.
A growing number of miRNAs are being experimentally cloned
from human tissues and a relatively large number of these
miRNAs are expressed in the brain [8,9]. The presence of
miRNAs in adult human brain tissues suggests that they are
involved in maintaining brain function [10]. At present, little is
known about the functional mechanisms, which are regulated by
brain-expressed miRNAs but predictions from computational
algorithms suggest that genes involved in ‘‘neurogenesis’’ are over-
represented among miRNA target genes [11]. Indeed, in vitro
studies have shown that miRNAs affects neuronal differentiation
[12,13] and identity [14]. Moreover, the studies, which have been
conducted so far, provide evidence that some miRNAs are
localized to the synaptosomal complex [15,16] and in depth
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PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e873characterization has shown that mir-134 modulate synapse
plasticity in rat hippocampus by repressing spine formation [17].
In addition, two miRNAs (lsy-6 and mir-273) have been
implicated in neuronal pattering during the formation of left-right
asymmetry of two morphologically bilateral taste receptor neurons
in Caenorhabditis elegans [18,19].
Due to their regulatory properties, their presumed pleiotropic
effects and their abundance in the brain, it has been suggested that
non-coding RNAs could be involved in the pathogenesis of
schizophrenia [5,20]. Some of the most consistent pathological
findings in schizophrenia includes abnormal cyto-architecture
[21], left-right asymmetry of brain hemispheres [22,23] as well as
reductions in dendritic spine density and the number of synapses
[24,25]. With the current knowledge that miRNAs are involved in
these processes and that alterations in the interactions between
miRNAs and their targets may form a potent source of phenotypic
variation, brain-expressed miRNAs qualify as candidate genes for
schizophrenia. A novel report on differential gene expression of 16
miRNAs in the prefrontal cortex in schizophrenia supports this
idea [26]. Therefore, we have investigated if genetic variants
within brain-expressed miRNAs are associated with schizophrenia
using a case-control study design.
METHODS
Identification of brain-expressed miRNAs from the
literature
A systematic search in PUBMED (release June 14. 2006) for
papers on brain-expressed miRNAs resulted in the identification of
14 references, which include data from microarray and Northern
Blotting studies. A total of 101 unique miRNA transcripts have
been detected in one or more regions of the human brain. SNPs
within +/2100 bp of the mature miRNA transcript were
identified from the human genome (NCBI build 36.1).
Genotyping
Genomic DNA was extracted from whole blood samples and the
samples were genotyped using the GoldenGate assay (Illumina
Inc) [27] on custom designed Illumina Bead Arrays at the geno-
typing facility at Uppsala University, Sweden. For this platform,
assay performance puts restrictions on the SNP panel that can be
tested. Assay performance is calculated as an estimated genotype
success rate for each SNP, which accounts for both SNP validation
status and assay design for the array. SNPs less than 60 bp apart
can not both be genotyped; when this occurred we selected the
SNP within the sequence coding for the mature miRNA, followed
by SNPs with the highest estimated success rate and finally SNPs
with the highest minor allele frequency (MAF). Based on these
criteria it was possible to genotype 31 SNPs within – or in the
vicinity of 28 microRNA genes.
Samples
This study included three independent population-based case-
control samples from Denmark, Sweden and Norway. The sample
characteristics of the three samples are summarized in table 1.
The Danish sample The Danish sample included 420
patients who have been recruited to Danish Psychiatric Biobank
from the psychiatric departments at the six hospitals in the
Copenhagen region. All patients had been clinically diagnosed
with schizophrenia according to ICD-10; F20 and F25 without
ever having received a diagnosis of mania or bipolar illness (F30-
31). An experienced research- and consultant psychiatrist verified
high reliability of the clinical diagnoses [28,29] using OPCRIT
semi-structured interviews. The vast majority of the patients (96%)
who fulfilled the ICD-10 criteria of schizophrenia also complied
with the corresponding DSM-IV standards. At the time of the last
assessment the patients had a mean age of 43.7 (+/212.0) years,
a mean age at onset of illness of 27.7 (+/29.2) years, a mean
duration of illness of 16.5 (+/210.3) and a mean duration of
hospitalization of 4.2 (+/24.5) years. None of these variables
differed significantly between men and women. The majority
(85%) of the patients were ethnical Danish, i.e. the patients and
both parents were born in Denmark, while in a minor fraction of
the cases (15%) one parent was Caucasian and born outside
Denmark in another North-western European country, primarily
in Sweden or Norway, secondarily in Germany, the Netherlands,
England or France.
The healthy controls subjects were recruited among 15,000
blood-donors from the Danish Blood Donor Corps in the
Copenhagen area. The Donor corps includes .5% of the Danish
population who donate blood on a voluntary and unpaid basis.
Apparent behavioral abnormality was an exclusion criterion and
all individuals stated that they felt completely healthy with
a possibility to discuss any health related issues with a physician.
Two unrelated healthy control subjects of Danish Caucasian
origin were matched to each patient on gender, year of birth and
month of birth, with matching ethicality.
The Danish Scientific Committees and the Danish Data
Protection Agency approved the study and all the patients have
give written informed consent prior to inclusion into the project.
The Swedish sample The Swedish sample included 257
patients who have been recruited from psychiatric clinics in
northwestern Stockholm County. All patients had been clinically
diagnosed with schizophrenia (n=226), schizophreniform disorder
(n=8) or schizoaffective disorder (n=25) according to DSM-III-
R/DSM-IV diagnostic criteria based on interviews and record
reviews as previously described [30–32]. At the time of the last
assessment the patients had a mean age of 43.6 (+/214.2) years,
a mean age at onset of illness of 24.6 (+/26.8) years, and a mean
duration of illness of 19.0 (+/213.8) years. Psychotic women were
older when entering the study (46.9+/215.5 years), and tended to
have a higher age at onset (25.8+/28.0 years) and a longer
duration of illness (21.0+/214.7 years) than men with psychosis
Table 1. Sample characteristics.
......................................................................
Schizophrenia Control
Sample Women (SD) Men (SD) Women (SD) Men (SD)
Denmark
N 179 241 418 588
Mean age 45.1 (12.5) 43.1 (12.0) 44.4 (12.2) 42.4 (11.3)
MAFA 27.0 (11.3) 25.7 (8.9)
Sweden
N 97 160 111 182
Mean age 57.1 (16.7) 52.3 (13.8) 50.7 (10.1) 50.1 (10.0)
MAFA 25.9 (8.0) 23.8 (5.9)
Norway
N8 8 7 5 9 8 7 9
Mean age 38.8 (11.5) 35.6 (9.8) 38.0 (10.2) 39.6 (10.2)
MAFA 27.3 (9.6) 26.8 (9.0)
Mean age is calculated as the expected mean age in 2006; MAFA: mean age at
first admission.
doi:10.1371/journal.pone.0000873.t001
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PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e873(41.6+/213.1, 23.9+/25.9 and 17.7+/213.2 years; Wilcoxon/
Kruskal Wallis tests p=0.007, p=0.07, and p=0.09, respec-
tively). All patients were Caucasian. Based on the birth country of
the grandparents or greater grandparents, 79%, 12% and 9% of
the patients were estimated to be of Swedish, Finnish or other
European origin, respectively.
The healthy control subjects were recruited among subjects
previous participating in biological psychiatric research at the
Karolinska Institute or drawn from a representative register of the
population in Stockholm County and interviewed as previously
described [31]. All controls were Caucasian and 86%, 6%, and 8%
were estimated to be of Swedish, Finnish or other European origin,
respectively. The mean age was 40.5 (+/29.8) years when entering
the study. None of the controls suffered from schizophrenia.
The Ethical Committee of the Karolinska Hospital, the
Stockholm Regional Ethical Committee and the Swedish Data
Inspection Board approved the study. All subjects participated
after giving informed consent.
The Norwegian sample The Norwegian sample included
163 patients who had been recruited to the TOP study from all the
psychiatric hospitals in the Oslo area. The patients had been
diagnosed according to Structural Clinical Interview for DSM-IV
(SCID) as schizophrenia (n=124) schizoaffective (n=31) and
schizophreniform (n=8). Two clinical professors continuously
trained and supervised a group of research fellows in order to
secure the quality of the clinical assessments. Reliability of the
diagnosis has recently been tested, and the percentage of
agreement was 82%, and Kappa 0.77 (95% CI: 0,60–0,94).
At the time of the last assessment the patients had a mean age of
37.1 (+/210.7) years, a mean age at onset of illness of 27.5 (+/
28.6) years (onset defined as age of first contact with psychiatric
health service), and a mean duration of illness of 10.6 (+/210.5)
years. None of these variables differed significantly between men
and women. The majority (90%) of the patients were ethnical
Norwegian, i.e. the patient and both parents were born in Norway,
while in a minor fraction of the cases (10%) one parent was born
outside Norway in another North-western European country.
The healthy control subjects were randomly selected from
statistical records of persons from the same catchments area as the
patient groups. Only subjects born in Norway were contacted by
letter and invited to participate. All controls were of Caucasian
origin; around 85% had two Norwegian parents, the rest one
parent from other European origin. Moreover, all participants had
to have Norwegian as their first language or have received their
compulsory schooling in Norway. The mean age of the control
subjects in 2006 was 39.0 (+/210.2). The control subjects were
screened by interview and with the Primary Care Evaluation of
Mental Disorders (PRIME-MD). None of the control subjects had
a history of moderate/severe head injury, neurological disorder,
mental retardation or an age outside the age range of 18–60 years.
Healthy subjects were excluded if they or any of their close
relatives had a lifetime history of a severe psychiatric disorder
(schizophrenia, bipolar disorder and major depression), a history
of medical problems thought to interfere with brain function
(hypothyroidism, uncontrolled hypertension and diabetes), or
significant illicit drug use.
The Norwegian Scientific-Ethical Committees and the Norwegian
Data Protection Agency approved the study and all patients have
given written informed consent prior to inclusion into the project.
Statistics
We have tested for allelic, genotypic – and in a few cases the
haplotype effect in each the of Scandinavian samples, and that of
the combined sample for those with p,0.1.
Test for Hardy-Weinberg (HW) proportions was performed by
chi-square exact tests implemented in the PLINK (v. 0.99r) [33]
on all heterozygous markers in cases and control subjects of each
Scandinavian sample. SNPs showing nominal HW disequilibrium
(p,0.05) in one or more control groups were removed from the
subsequent analyses in the corresponding sample(s). The hetero-
geneity between the three Scandinavian samples was estimated by
calculating the fixation index of the all SNPs in the healthy
controls, using Stucture2.2 [34]. In addition, Breslow-Day test was
used to evaluate the homogeneity of the odds ratios between the
three samples.
Test for allelic association and genotypic effects was calculated
for all three Scandinavian samples separately and combined using
a standard chi squared test. Subsequently, the Cochran-Mantel-
Haenszel test for 2626k tables was used to perform a combined
analysis of all three samples for all markers with p,0.10 in one or
more samples.
PLINK (v. 0.99r) [33] was used to perform the Breslow-Day
test, allele and genotypes association analysis and the Cochran
Mantel-Haenszel test. The odds ratio (w. 95% confidence interval
(CI
95)) was manually calculated for nominal significant SNPs.
Three SNPs were genotyped for the hsa-let-7a-3 gene. LD
blocks were first defined from the genotype data using the default
setting in HAPLOVIEW [35] in all three sample for both
schizophrenic patient and control subjects separately. UN-
PHASED (v. 3.0.3) [36,37] was then used to estimate haplotype
phases, to test for haplotype main effects and to estimate relative
risk of individual haplotypes.
Network identification
The two miRNAs that that showed nominally significant
association in the analyses were further analyzed using TargetS-
canS[8] to identify their predicted gene targets. Genes that were
targeted by both miRNAs were identified. This common target
(CoT) list was then analyzed using Biomolecular Object Network
Databank (BOND
TM) to identify all their known protein- or DNA-
interaction partners. The resulting interaction network of CoTs
and interaction partners was analyzed and visualized using
Cytoscape[38] to identify potential network(s).
RESULTS
We selected 101 miRNA genes with known expression in the
human brain, by systematic review of the public miRNA
literature. In these we identified 46 SNPs within the mature
miRNA sequence and in the adjacent +/2100 bp genomic
regions that presumably could interfere with miRNA function (i.e.
affecting the promoter activity, splicing of the pre-miRNA etc.) or
serve as tags for potential unknown SNPs situated within the
coding region.
Of the 46 identified SNPs we were able design assays for 31
SNP loci in 28 miRNA gene regions using the IlluminaH chip
platform (see Methods). Allele frequencies for these 31 SNPs in the
Danish, Swedish and Norwegian samples are listed in table 2 and
shown to be similar across the three samples. Ten loci were found
to be monomorphic, while two SNPs had very low MAF and were
only represented in one of the three control samples (Table 2).
The remaining 19 miRNA-loci did not deviate significantly
from the expected Hardy-Weinberg proportions, with the
exception of rs3807348 that was in disequilibrium in the Danish
control group (p=0.039). This SNP was not analyzed further in
the Danish sample (table 2). Further, rs10865292 did deviate
significantly from the expected Hardy-Weinberg proportions in
the Danish patient sample (data not shown), but the SNP was not
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calculated the mean Fixation Index for all informative SNPs
(Fst=0.0013), and found no sign of stratification between the three
Scandinavian samples.
Among the 18 loci, one SNP (rs17578796) in hsa-mir-206 (mir-
206) showed overall significant allelic association with schizophre-
nia (unadjusted p=0.041, table 2), with the main contribution
coming from the Danish sample (unadjusted p=0.002). The odds
ratios of the combined and the Danish samples suggest that the
minor allele increases the susceptibility to schizophrenia
(OR=1.86 (CI
95 1.03–3.36) and OR=3.52 (CI
95 1.54–8.08,
respectively). Furthermore, one SNP (rs1700) in hsa-mir-198 (mir-
198) showed significant association with disease in the Norwegian
sample (unadjusted p=0.038) with the minor allele being
protective (OR=0.48 (CI
95 0.24–0.96). The Breslow-Day test
for homogeneity of both rs17578796 and rs1700 were significant,
indicating that there are heterogeneity of the odds ratios in the
three populations, and thus consistent with the observed lack of
significant association in the overall sample.
Haplotype analysis was done for the hsa-let-7a-3 gene region
where 3 SNPs were genotyped pair wise LD (D9) for these 3 SNPs
were above 0.98, and there were no association of hsa-let-7a-3
haplotypes overall or in the three population individually (P.0.2).
Correcting for multiple testing (16 independent tests were
performed as three of the 18 examined SNPs in hsa-let-7a3 are in
strong LD) using Bonferroni correction yields an adjusted the
significance level P=0.05/16,0.003, which were obtained only
by rs17578796 in the Danish sample.
To elucidate the biological signaling network implicated in
schizophrenia in this study, the predicted targets of the two
associated miRNAs (rs17578796 and rs1700) were identified using
TargetScanS. This analysis revealed 440 genes and 148 genes
targeted by mir-206 and mir-198, respectively, of which 15 genes
were common targets (CoT) of both miRNAs. The first-degree
protein- and DNA-interaction partners of the 15 CoTs were
identified using BOND
TM in order to construct the signaling
networks in which they operate. These networks were analyzed
and visualized using Cytoscape.
Seven networks included only a single CoT and were therefore
not analyzed further. One interesting network, however, included
eight CoTs connected by three interaction partners (the
transcription factors TAF1, JUN and ATF2), as shown in
figure 1. Interestingly, two of the genes in this network have
previously been associated with schizophrenia as deregulated in
postmortem brains (CCND2 [39]) or positioned under a highly
significant linkage peak (PTPN1[40]). Also, the three interaction
partners are expressed in prefrontal cortex (according to GNF
SymAtlas v1.2.4) that has been implicated in schizophrenia[41].
Finally, JUN is up-regulated in post-mortem brains of schizophre-
nia patients[42] whereas the neuro-specific expression of TAF1
has been related to another neurological disorder: X-linked
dystonia-parkinsonism[43].
DISCUSSION
To our knowledge this is the first study on genetic variation in
miRNA in relation to schizophrenia. The list of known miRNAs is
continuously growing and with that the number of miRNAs
known to be expressed in the brain. We have analyzed 31 miRNA
variants - or approximately three-quarters of the identified
polymorphic loci – located in 28 miRNA gene regions or one
fourth of the miRNAs expressed in the developing- or adult
human brain (28). We find that of the 31 SNPs genotyped, ten
were monomorphic in all three Scandinavian samples, two had
very low frequency and one deviated from that distribution
expected under Hardy-Weinberg proportions in one of the control
samples.
Among the remaining 18 SNPs, we find significant allelic
association of two SNPs. In mir-198, rs1700 was found associated
with schizophrenia only in the Norwegian sample, while the
rs17578796 (in mir-206) was disease associated in the total sample
and the Danish, the latter being resistant to correction for multiple
testing. The two SNPs are positioned in the region flanking the
miRNA genes and are therefore unlikely to interfere directly with
the biological activity of the miRNAs. Our findings are not
consistent across the three samples, illustrated by the heterogeneity
of the odds-ratio of both mir-206 and mir-198 (Breslow-Day test,
table 2). Though the frequency of rs17578796 resembles that of
the reported in Europeans by dbSNP(NCBI), its low frequency
highlight the requirement for additional genotyping of indepen-
dent samples to exclude type I error. Given that the observed
associations are indeed true, this heterogeneity merits particular
attention.
First, Scandinavians are generally considered to be well suited
for genetic (replication-) studies, being ethnically homogeneous
populations that only recently have been subject to non-Caucasian
immigration. This notion is ensured as all study subjects are born
in the Scandinavia and the vast majority has two Scandinavian
born parents. A small minority has one Caucasian parent born in
North-Western Europe, but outside Scandinavia. However,
exclusion of patients with one non-Danish parent from the Danish
sample had no effect on the results (data not shown). This is
consistent with the recent study by the Welcome Trust
Consortium seems to suggest that ethnic admixture is of little
concern in genetics studies once non-European immigration is
eliminated from the study [44]. This does not exclude, however,
that even the limited presence of subjects with partly Finnish
ancestry in the Swedish sample may introduce a bias that in this
study may have blurred true positive findings. To test the notion of
relatively homogeneous Scandinavian populations within the
experimental setting of this study, we estimated the mean Fixation
Figure 1. MicroRNA Network. Legend: Circles represent genes with
their official HUGO symbols. Grey filled=mir 206/198 targets, white
filled=first-degree interaction proteins. Diamond shape=Genes pre-
vious found associated with schizophrenia. A Line symbolize an
interaction, in which arrow=DNA-protein interaction and no arrow=
protein-protein interaction.
doi:10.1371/journal.pone.0000873.g001
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(Fst=0.0013), a confounding effect on a single locus cannot be
excluded.
Second, the diagnostic reliability of the three samples has been
ascertained thoroughly and is unlikely to be the cause of the
observed heterogeneity. In contrast, the three samples are different
in other clinical aspects that may confound our findings. Most
importantly, the Norwegian patients are generally younger with
a shorter duration of illness than the considerably more chronic
and poor outcome of the Danish and Swedish patients.
Finally, the observed association may arise from the two SNPs
being in LD with unknown, causal at-risk alleles in the miRNA
genes. These might be located outside – and even quite distant
from – the selected gene region that we have targeted in this study,
e.g. in the promoter region of the coding (host) genes in which
many miRNAs are embedded. Alternatively, the genotyped SNPs
may capture a number of very low frequency or ‘private’ SNPs in
the miRNAs that will only be discovered by direct sequencing.
By in-silico analysis, we find fifteen targets shared by the two
miRNAs. This constitutes more than a five-fold over-representa-
tion compared to the expected (2.7 common targets (CoTs)) of
a random selection of miRNAs targets among the roughly 24,000
known human genes. Furthermore, we find that eight of these 15
CoTs are located in a remarkably simple or compact signaling
network with several components having been implicated in
schizophrenia or related brain disorders [39–43]. This finding
lends support to the associations observed in our study, but also
suggest that the identified candidate network should be further
investigated based on the hypothesis that multiple variants
independently or combined may perturb the biological activity
of the network.
ACKNOWLEDGMENTS
Authors wish to thank patients who participated and made this study
possible. Authors also acknowledge expert assistance by numerous mental
health professionals in the various clinical departments as well as helpful
discussions with Drs. Jan Egebjerg and Jan Torleif Pedersen at H.
Lundbeck A/S (Denmark).
Author Contributions
Conceived and designed the experiments: TH TW LO ML. Performed the
experiments: TH LO. Analyzed the data: TH LO. Contributed reagents/
materials/analysis tools: KJ HU EJ OA SD IM IA HH ST AW. Wrote the
paper: TH LO.
REFERENCES
1. McGuffin P, Owen MJ, O’Donovan MC, Thapar A, Gottesman II (1994)
Seminars in psychiatric genetics. London: Geskell press. pp 100.
2. Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, et al. (2005)
Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution.
Science 308: 1149–1154.
3. Frith MC, Pheasant M, Mattick JS (2005) The amazing complexity of the
human transcriptome. Eur J Hum Genet 13: 894–897.
4. Kapranov P, Cawley SE, Drenkow J, Bekiranov S, Strausberg RL, et al. (2002)
Large-scale transcriptional activity in chromosomes 21 and 22. Science 296:
916–919.
5. Perkins DO, Jeffries C, Sullivan P (2005) Expanding the ‘central dogma’: the
regulatory role of nonprotein coding genes and implications for the genetic
liability to schizophrenia. Mol Psychiatry 10: 69–78.
6. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of
translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:
515–524.
7. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, et al. (2005) The
widespread impact of mammalian MicroRNAs on mRNA repression and
evolution. Science 310: 1817–1821.
8. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets. Cell
120: 15–20.
9. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, et al. (2004)
Expression profiling of mammalian microRNAs uncovers a subset of brain-
expressed microRNAs with possible roles in murine and human neuronal
differentiation. Genome Biol 5: R13.
10. Mehler MF, Mattick JS (2006) Non-coding RNAs in the nervous system.
J Physiol 575: 333–341.
11. John B, Enright AJ, Aravin A, Tuschl T, Sander C, et al. (2004) Human
MicroRNA targets. PLoS Biol 2: e363.
12. Krichevsky AM, Sonntag KC, Isacson O, Kosik KS (2006) Specific microRNAs
modulate embryonic stem cell-derived neurogenesis. Stem Cells 24: 857–864.
13. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, et al. (2005) A
cAMP-response element binding protein-induced microRNA regulates neuronal
morphogenesis. Proc Natl Acad Sci U S A 102: 16426–16431.
14. Conaco C, Otto S, Han JJ, Mandel G (2006) Reciprocal actions of REST and
a microRNA promote neuronal identity. Proc Natl Acad Sci U S A 103:
2422–2427.
15. Kim J, Krichevsky A, Grad Y, Hayes GD, Kosik KS, et al. (2004) Identification
of many microRNAs that copurify with polyribosomes in mammalian neurons.
Proc Natl Acad Sci U S A 101: 360–365.
16. Lugli G, Larson J, Martone ME, Jones Y, Smalheiser NR (2005) Dicer and
eIF2c are enriched at postsynaptic densities in adult mouse brain and are
modified by neuronal activity in a calpain-dependent manner. J Neurochem 94:
896–905.
17. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, et al. (2006) A
brain-specific microRNA regulates dendritic spine development. Nature 439:
283–289.
18. Chang S, Johnston RJ Jr, Frokjaer-Jensen C, Lockery S, Hobert O (2004)
MicroRNAs act sequentially and asymmetrically to control chemosensory
laterality in the nematode. Nature 430: 785–789.
19. Johnston RJ, Hobert O (2003) A microRNA controlling left/right neuronal
asymmetry in Caenorhabditis elegans. Nature 426: 845–849.
20. Rogaev EI (2005) Small RNAs in human brain development and disorders.
Biochemistry (Mosc) 70: 1404–1407.
21. Arnold SE, Talbot K, Hahn CG (2005) Neurodevelopment, neuroplasticity, and
new genes for schizophrenia. Prog Brain Res 147: 319–345.
22. Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the
data and their interpretation. Brain 122(Pt 4), 593–624.
23. Harrison PJ (2004) The hippocampus in schizophrenia: a review of the
neuropathological evidence and its pathophysiological implications. Psycho-
pharmacology (Berl) 174: 151–162.
24. Davidsson P, Gottfries J, Bogdanovic N, Ekman R, Karlsson I, et al. (1999) The
synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in
thalamus and related cortical brain regions in schizophrenic brains. Schizophr
Res 40: 23–29.
25. Glantz LA, Lewis DA (2000) Decreased dendritic spine density on prefrontal
cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57: 65–73.
26. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, et al. (2007)
microRNA expression in the prefrontal cortex of individuals with schizophrenia
and schizoaffective disorder. Genome Biol 8: R27.
27. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, et al. (2003) Highly
parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 68: 69–78.
28. Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas J, et al. (2005)
Reliability of Clinical ICD-10 Schizophrenia Diagnoses. Nordic Journal of
Psychiatry 59: 209–212.
29. Jakobsen KD, Frederiksen JN, Parnas J, Werge T (2006) Diagnostic Agreement
of Schizophrenia Spectrum Disorders among Chronic Patients with Functional
Psychoses. Psychopathology 39: 269–276.
30. Ekholm B, Ekholm A, Adolfsson R, Vares M, Osby U, et al. (2005) Evaluation of
diagnostic procedures in Swedish patients with schizophrenia and related
psychoses. Nord J Psychiatry 59: 457–464.
31. Jonsson EG, Edman-Ahlbom B, Sillen A, Gunnar A, Kulle B, et al. (2006) Brain-
derived neurotrophic factor gene (BDNF) variants and schizophrenia: an
association study. Prog Neuropsychopharmacol Biol Psychiatry 30: 924–933.
32. Vares M, Ekholm A, Sedvall GC, Hall H, Jonsson EG (2006) Characterization
of patients with schizophrenia and related psychoses: evaluation of different
diagnostic procedures. Psychopathology 39: 286–295.
33. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: A Tool Set for Whole-Genome Association and Population-Based
Linkage Analyses. Am J Hum Genet 81: 559–575.
34. Falush D, Stephens M, Pritchard JK (2003) Inference of population structure
using multilocus genotype data: linked loci and correlated allele frequencies.
Genetics 164: 1567–1587.
35. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
36. Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes.
Genet Epidemiol 25: 115–121.
37. Dudbridge F (2006) UNPHASED user guide. .
38. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape:
a software environment for integrated models of biomolecular interaction
networks. Genome Res 13: 2498–2504.
MiRNA in Schizophrneia
PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e87339. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. (2004)
Mitochondrial dysfunction in schizophrenia: evidence for compromised brain
metabolism and oxidative stress. Mol Psychiatry 9: 684–97, 643.
40. Freedman R, Leonard S, Olincy A, Kaufmann CA, Malaspina D, et al. (2001)
Evidence for the multigenic inheritance of schizophrenia. Am J Med Genet 105:
794–800.
41. Tamminga CA, Holcomb HH (2005) Phenotype of schizophrenia: a review and
formulation. Mol Psychiatry 10: 27–39.
42. Aston C, Jiang L, Sokolov BP (2004) Microarray analysis of postmortem
temporal cortex from patients with schizophrenia. J Neurosci Res 77: 858–866.
43. Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, et al. (2007) Reduced
neuron-specific expression of the TAF1 gene is associated with X-linked
dystonia-parkinsonism. Am J Hum Genet 80: 393–406.
44. The Wellcome Trust Case Control Consortium (2007) Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447: 661–678.
MiRNA in Schizophrneia
PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e873